District Court, D. Delaware July 22, 2013, Civ. No. 11-164-SLR (Cephalon Inc. v. Mylan Pharmaceuticals Inc.)

Also known as

United States · · · 22-07-2013

OPINION

SUE L. ROBINSON, District Judge.

I. INTRODUCTION

This Hatch-Waxman action arises out of the filing of an Abbreviated New Drug Application (“ANDA”) by defendants Mylan Pharmaceuticals Inc. and Mylan Inc. (collectively, “Mylan”) seeking to market generic fentanyl buccal tablets. Plaintiff Cephalon Inc. is the holder of approved New Drug Application (“NDA”) No.

Read the full text

This document is published by courtlistener.com.

Moonlit adds the citation network, article-level links and cross-references, which are available to search for free.